Lisinopril for chf
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that lisinopril effectively improves exercise duration, left ventricular function, and symptoms in congestive heart failure patients, though its absorption may be reduced in hospitalized patients and it may be less effective than valsartan in modulating sympathetic activity.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta18 papers analyzed
Lisinopril for Congestive Heart Failure (CHF)
Introduction to Lisinopril and CHF
Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor commonly used in the treatment of congestive heart failure (CHF). CHF is a condition where the heart is unable to pump blood effectively, leading to symptoms such as shortness of breath, fatigue, and fluid retention. Lisinopril helps manage these symptoms by relaxing blood vessels, reducing blood pressure, and improving heart function.
Efficacy of Lisinopril in CHF Treatment
Improvement in Exercise Capacity and Heart Function
Several studies have demonstrated the efficacy of lisinopril in improving exercise capacity and heart function in CHF patients. In a 12-week randomized, double-blind trial involving 130 patients, lisinopril significantly improved exercise duration, left ventricular ejection fraction (LVEF), and clinical symptoms compared to placebo. Another study with 10 CHF patients showed an increase in maximal oxygen uptake with lisinopril treatment. Additionally, a comparison with captopril in 189 patients revealed that lisinopril was equally effective in increasing treadmill exercise times and was particularly beneficial for patients with renal impairment.
Autonomic Nervous System and Sympathetic Activity
Lisinopril has also been compared with valsartan, an AT1 receptor antagonist, in terms of their effects on the autonomic nervous system in CHF patients. Both drugs showed comparable effects on heart rate variability and baroreflex sensitivity. However, valsartan was more effective in reducing plasma norepinephrine levels, indicating a greater reduction in sympathetic activity.
Pharmacokinetics and Absorption
The pharmacokinetics of lisinopril in CHF patients indicate reduced absorption compared to normal subjects. In a study involving 12 in-patients with stable CHF, the mean urinary recovery of lisinopril was significantly lower following oral administration compared to intravenous administration, suggesting altered drug disposition in CHF patients. Despite this reduced absorption, lisinopril still demonstrated potent ACE inhibition and hemodynamic efficacy.
Comparison with Other ACE Inhibitors
Lisinopril vs. Captopril
In older patients with CHF, lisinopril and captopril both improved exercise duration and symptomatic relief. However, lisinopril showed a tendency to be more effective, particularly in improving LVEF, which is associated with a better prognosis. Both drugs were well-tolerated, but lisinopril was noted for its longer duration of action.
High-Dose Tolerability
The ATLAS trial examined the safety and tolerability of high-dose lisinopril compared to low-dose treatment in CHF patients. The study found that high doses of lisinopril were generally well-tolerated, with a similar rate of adverse events and withdrawals compared to low doses. This suggests that more aggressive use of lisinopril is warranted in CHF management.
Long-Term Safety and Tolerability
Long-term studies have confirmed the safety of lisinopril in CHF treatment. An analysis of over 1,000 patients treated with lisinopril for up to four years showed that the drug was well-tolerated, with a similar range of adverse events compared to other ACE inhibitors like enalapril and captopril. The most common adverse events were related to renal function, but these were rarely of significant consequence.
Special Populations: Renocardiac Syndrome
In patients with chronic renocardiac syndrome, lisinopril has shown effectiveness in improving left ventricular diastolic function and myocardial relaxation. This improvement in diastolic function is crucial for managing CHF in patients with concurrent renal issues.
Combination Therapy
Combining lisinopril with other medications has shown additional benefits. For instance, a study comparing lisinopril alone to a combination of lisinopril and Mildronate found that the combination therapy led to greater improvements in symptoms, NYHA functional class, and exercise capacity.
Conclusion
Lisinopril is a highly effective and well-tolerated ACE inhibitor for the treatment of CHF. It improves exercise capacity, heart function, and symptoms in CHF patients. While it shows reduced absorption in CHF patients, its overall efficacy remains significant. Lisinopril compares favorably with other ACE inhibitors and can be safely used in high doses. Additionally, it offers benefits in special populations and when used in combination therapy. These findings underscore the importance of lisinopril as a valuable option in the management of CHF.
Sources and full results
Most relevant research papers on this topic
